IsoPet canine soft-tissue sarcoma treatment delivers 'complete response'September 28, 2018Vivos Inc., a pharmaceutical company that develops minimally invasive treatments to combat cancer in humans and animals, reported that its signature product, IsoPet, was used to treat a hind-leg soft-tissue sarcoma in a Shetland sheepdog at the University of Missouri Veterinary Health Center in Columbia, Mo. The treatment of the sarcoma resulted in a "complete response," meaning tumor destruction and disappearance, together with a healthy recovery, according to veterinary oncologist Charles Maitz, DVM, PhD, DACVR-RO. Results will be presented in at the Veterinary Cancer Society's annual conference in Louisville, Ky., Oct. 17 - 20. Post-treatment imaging and dosimetry provided confirmatory data addressing questions previously raised by U.S. Food and Drug Administration review panel, including: Near-uniform placement by injection and interstitial perfusion within the tumor without vascular clearance to normal organs and tissues Very high therapeutic ratios (radiation dose to the tumor relative to normal organs) Effective, highly localized, high-dose radiotherapy, and complete absence of adverse side-effects in critical normal tissues The University of Missouri is now advertising availability of IsoPet treatment for dogs and other species, including treatment of equine sarcoids. "The successful treatment of the cat and dog subjects thus far increases the likelihood of …
SPONSORED CONTENTDon't just protect. Triple protect.One tasty monthly chew. Approved for puppies as young as 8 weeks, weighing at least 2.8 lbs. + Learn more
